Study of dostarlimab plus chemotherapy for advanced or recurrent endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage III or IV) or recurrent endometrial cancer that has come back after initial treatment
- Your tumor has a specific genetic marker called dMMR or MSI-H (your doctor can test for this)
- You have at least one tumor that can be measured on a scan
- You have not received chemotherapy or other systemic treatment for your current endometrial cancer (unless it was previous adjuvant therapy and the cancer came back more than 6 months after finishing that treatment)
- You are in generally good health (able to do daily activities without help) and have adequate organ function
- You are not pregnant or breastfeeding and agree to use effective birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called dostarlimab (an immunotherapy that helps your immune system fight cancer) in people with advanced or recurrent endometrial cancer. The goal is to see if the drug is safe and effective for this type of cancer.
This study is testing the safety of an immunotherapy drug called dostarlimab (Jemperli) in patients with a type of endometrial cancer that has returned, spread, or not improved after previous chemotherapy. The drug works by helping your immune system fight the cancer, and the study is specifically for patients whose tumors have certain genetic features (dMMR or MSI-H).
This trial tests a new drug (mocertatug rezetecan) compared to standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. It may help if your tumor has a protein called B7-H4.
This trial tests a new drug called dostarlimab, given with standard chemotherapy, for people with advanced or recurrent endometrial cancer. It aims to see if this combination can help shrink tumors or slow their growth.
This trial tests whether giving the drug dostarlimab before surgery can shrink or control endometrial cancer. It is for people whose tumors have a specific genetic feature (MMR deficiency) that may make the drug more effective.
This trial tests whether giving a drug called dostarlimab (an immunotherapy that boosts your immune system to fight cancer) before and after surgery can help treat advanced endometrial cancer. It is for people with stage 3 or 4 endometrial cancer who haven't had treatment yet and may be eligible if their tumor has a specific marker called mismatch repair deficiency.
Hear when a new Neoplasms, Endometrial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.